SYT (SS18) Breakapart
Synovial sarcomas account for up to 10% of soft-tissue sarcomas, typically arising in the para-articular regions in adolescent and young adults1.
A characteristic SYT(SS18)-SSX fusion gene resulting from the chromosomal translocation t(X;18)(p11;q11.2) is detectable in more than 90% of synovial sarcomas2, suggesting this is the primary causal event. The translocation fuses the SYT gene from chromosome 18q11.2 to either of two highly homologous genes at Xp11: SSX1 (Synovial Sarcoma X Breakpoint 1) or SSX2. In less than 1% of cases, SYT will be fused to a third gene, SSX43. SYT-SSX1 and SYT-SSX2 are thought to disrupt transcription and the subsequent expression of specific target genes4,5.
It was very important for us to have more consistent results with our probes — easy-to-read bright signals and a range of vial sizes, which is much more cost-effective. It also was critical to upgrade our pretreatment kit to expedite the analysis of FFPE samples. We can now complete the process in about 90 minutes. Janet M. Cowan, PhD, Director of the Cytogenetics Laboratory at Tufts Medical Center
1. Enzinger FM, Weiss SW. Synovial sarcoma. In: Enzinger FM, Weiss SW, eds. Soft tissue tumors, 3rd ed. St. Louis: Mosby-Year Book, 1995:757–86
2. Sreekantaiah et al., Am J Pathol 1994;144:1121-34
3. Ladanyi et al., Canc Res 2002;62:135-40
4. Ladanyi et al., Diagn Mol Pathol 1995;4:162-73
5. Sorensen, Triche, Semin Cancer Biol 1996;7:3-14
- Area of Interest*
This product is intended to be used on formalin-fixed paraffin-embedded (FFPE) tissues.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.